Ventyx Biosciences (NASDAQ:VTYX) files prospectus the offer and resale from time to time of up to 7,060,100 shares of common stock. SEC Filing More on Ventyx Biosciences Ventyx Biosciences: R ...

EST Ventyx Biosciences (VTYX) files to sell 7.06M shares of common stock for holders Published first on TheFly – the ultimate ...

In his iconic song The Gambler, Kenny Rogers famously sang, “Every hand’s a winner, and every hand’s a loser.” This line offers valuable ...

Sanofi will keep a significant stake in the ... in their technology within immunology and neurology. We've invested in Ventyx, focused in autoimmune and inflammatory disorders with an NLRP3 ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

Sanofi reported third-quarter earnings and sales that beat analysts' expectations, boosted by earlier-than-anticipated deliveries of flu and respiratory syncytial virus vaccines and growing demand ...

zacks.com reported 2024-09-24 that Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232. Ventyx Biosciences ...

Advt The open offer has been triggered by Sanofi and CD&R entering into exclusive negotiations for the potential sale and purchase of a 50 per cent controlling stake in Opella, Sanofi's consumer ...

Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder With 11,000 talented and passionate people bringing iconic ...

Sanofi said on Monday (Oct 21) it had entered exclusive talks for the sale of a 50 per cent controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice ...